Lilly Q3 Profit Rises 16%; Lifts FY26 Sales View, Trims Adjusted Earnings Outlook
Eli Lilly (LLY) reported Q3 net income of $6.45B (+16% YoY) and revenue of $24.40B (+39% YoY), driven by Mounjaro and Zepbound sales. The company raised its FY26 revenue outlook to $91B-$92B but lowered adjusted EPS guidance to $35.00-$36.00 due to acquisition-related charges. Shares rose 4.02% in pre-market trading.
How this was made
The 30-second read
Why it matters
The earnings beat and raised revenue guidance drove a 4% pre‑market rally, while the earnings guidance trim may limit further upside.
Market read
Large‑cap biotech earnings with mixed guidance provide a short‑term trading opportunity and longer‑term sector implications.
What to watch
Acquired in‑process R&D charges and integration costs could weigh on near‑term profitability more than reflected in the guidance.
Background
Eli Lilly's Q3 results feature strong sales from Mounjaro and Zepbound, significant revenue growth, and a revised performance margin outlook.
Ticker impact
Eli Lilly reported Q3 results with 16% profit rise, raised FY26 revenue outlook, and trimmed adjusted earnings guidance.
modest upside as market prices in higher revenue outlook, with potential pressure from lower earnings guidance
Revenue guidance increase signals growth, while earnings guidance reduction introduces downside risk; the net effect is a slight positive bias reflected in the pre‑market rally.
Market effects
Strong performance reinforces bullish sentiment for the biotech/pharma sector, especially diabetes and obesity drug markets.
Positive for US large‑cap biotech stocks, may lift broader Nasdaq health‑care index.
Highlights continued demand for obesity treatments worldwide, could influence global pharma peers.
Counterpoint
Investors may view the earnings guidance cut as a red flag, suggesting margin pressure despite revenue growth.
Key entities
- companyEli Lilly and Company
US‑listed pharmaceutical company reporting Q3 results.
